Introduction Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. In the United States, it was available in both prescription and over-the-counter forms and was widely prescribed by doctors. Unfortunately, in 2020, the Food and Drug Administration (FDA) announced the recall of Etodolac due to concerns over its safety. In this article, we will explore why this popular pain medication was discontinued and what this means for doctors and patients alike.
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that was used to treat mild to moderate pain and inflammation. It was available both as a prescription medication and as an over-the-counter medication. It was widely prescribed by doctors for a variety of conditions including arthritis, menstrual cramps, and other musculoskeletal conditions.
The FDA announced the recall of Etodolac in 2020 due to safety concerns. The FDA noted that the drug had been associated with an increased risk of serious cardiovascular events, including heart attack and stroke. Additionally, the FDA noted that the drug had been associated with an increased risk of gastrointestinal bleeding. As a result, the FDA determined that the risks associated with Etodolac outweighed the benefits and recommended that it be discontinued.
For doctors, the discontinuation of Etodolac means that they can no longer prescribe it to their patients. However, doctors can still prescribe other NSAIDs to treat pain and inflammation. Additionally, doctors should be aware of the potential risks associated with other NSAIDs and should only prescribe them when the benefits outweigh the risks. For patients, the discontinuation of Etodolac means that they may need to find an alternative medication to treat their pain and inflammation. Patients should speak to their doctor about other options that may be available to them. Additionally, patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. Unfortunately, in 2020, the FDA announced the recall of Etodolac due to safety concerns. This means that doctors can no longer prescribe it to their patients and patients may need to find an alternative medication to treat their pain and inflammation. Doctors and patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
1.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
2.
An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.
3.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
4.
Breast cancer surgery: Study finds overnight hospital stay not important for older patients
5.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
1.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
2.
Exploring the Latest Treatments for Essential Thrombocythemia
3.
Colon cancer: Risk factors, warning signs and treatment options
4.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
5.
Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Thromboprophylaxis In Medical Settings- An Update
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation